

”

*We must have  
perseverance and above  
all confidence in ourselves.  
We must believe that we  
are gifted for something  
and that this thing must  
be attained.*

MARIE SKŁODOWSKA-CURIE



## CONTACT

### SECRET-ITN Team

Institute for Cell Biology and Immunology  
University of Stuttgart

Allmandring 31  
70569 Stuttgart  
Germany

### Program Manager

Dr. Raluca Tamas  
Tel: +49 711 685 66992  
E-mail: raluca.tamas@izi.uni-stuttgart.de

### Program Coordinator

Dr. Angelika Hausser  
E-mail: angelika.hausser@izi.uni-stuttgart.de



Find us on: [@ItNSecret](#)



<https://secret-itn.eu/>

[@SECRET-ITN](#)

[Linked in](#)


An H2020 MSCA project  
11 Beneficiaries  
8 Countries  
15 Early Stage Researchers

Exploitation of the  
**SECRETory**  
pathway for cancer  
therapy to address  
European research

**SECRET-ITN**

## SECRET – an MSCA ITN

The project explores the **SECRET**ory pathway regulation and its contribution to cancer by providing a highly qualified platform for European research training of bright young scientists. The aim of SECRET is to define secretory pathway-linked **biomarker genes** suitable for cancer diagnosis and prognosis, while offering cutting edge training to young scientists.



Despite strong efforts, breast cancer (BC) and colorectal cancer (CRC) still account for 7% and 13%, respectively, of all deaths from cancer in Europe in both sexes. In the case of triple-negative BC (TNBC, lacking hormone and HER2 receptor expression) accounting for 15% of all BC cases, there are no targeted therapies.

## Scientific Goal

**Dysregulated secretion is major driver of cancer progression** and holds promise as a **general therapeutic target** for the treatment of solid cancers including TNBC and CRC, irrespective of the mutational status. However, strategies for therapeutic exploitation of the secretory pathway are still in their infancy.

The incomplete understanding of how the secretory pathway is dysregulated **hinders efforts to exploit the secretory pathway for therapeutic and diagnostic purposes.**

The overall research objective of **SECRET** is to drive the understanding of the mutual regulation of the secretory pathway and cell signalling in cancer, which will serve as a platform to **identify and interrogate novel diagnostic and therapeutic strategies** for application in TNBC and CRC.



*SECRET has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 859962.*

## Training Aims

**SECRET Early Stage Researchers (ESRs)** will

- interrogate the impact of secretion to TNBC and CRC progression
- participate in a **training network** combining researchers with different expertise from academia and industry
- be a part of an **interdisciplinary and intersectoral** platform integrating cell biology, systems biology, proteomics, molecular biology, biochemistry, organoid and animal models, and computational modelling

